Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$283.21
neg -1.50
-0.54%
Today's Range: 266.00 - 285.81 | BIIB Avg Daily Volume: 1,938,300
Last Update: 02/24/17 - 12:08 PM EST
Volume: 794,138
YTD Performance: 10.06%
Open: $285.01
Previous Close: $284.75
52 Week Range: $223.02 - $338.51
Oustanding Shares: 215,951,945
Market Cap: 62,114,257,940
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 11 9
Moderate Buy 1 1 1 1
Hold 4 4 4 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.53 1.53 1.78
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 16.99
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
16.99 17.00 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.89% 16.23% -10.08%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.70 0.18
Net Income 2.90 1.00 0.25
EPS 10.40 1.20 0.29
Earnings for BIIB:
EBITDA 4.28B
Revenue 10.13B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $4.97 $5.14 $20.94 $22.47
Number of Analysts 20 20 19 21
High Estimate $5.28 $5.38 $21.48 $23.83
Low Estimate $4.27 $4.51 $20.28 $19.18
Prior Year $4.79 $5.21 $20.22 $20.94
Growth Rate (Year over Year) 3.77% -1.37% 3.55% 7.30%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Jim Cramer

 | Feb 8, 2017 | 11:24 AM EST
Jim Cramer compares Allergan's growth to other pharma stocks.
RMPIA

bullishBiogen upgraded at Citi

Feb 7, 2017 | 7:01 AM EST
BIIB was upgraded to Buy, Citigroup said. $305 price target. See positive risk/reward for the MS product line.
RMPIA
By

James "Rev Shark" DePorre

 | Feb 1, 2017 | 10:51 AM EST
The Fed is simply not a market catalyst this time.
RMPIA
Jan 23, 2017 | 11:18 AM EST
A merger would be smart, profitable ... and attention-grabbing.
RMPIA
By

David Katz

 | Jan 8, 2017 | 2:00 PM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

David Katz

 | Jan 6, 2017 | 7:00 AM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

Bret Jensen

 | Jan 3, 2017 | 11:00 AM EST
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
RMPIA
By

Bruce Kamich

 | Dec 28, 2016 | 1:43 PM EST
With weak chart patterns and a quantitative downgrade, longs should protect their positions.
RMPIA
By

Doug Kass

 | Dec 27, 2016 | 10:00 AM EST
Six reasons why the Nasdaq 100 ETF seems ready to pull back.
RMPIA
By

Doug Kass

 | Dec 27, 2016 | 7:00 AM EST
Microsoft (MSFT) , which makes up about 8.6% of the index. Amazon (AMZN) , which has about a 6.4% weighting. Cisco (CSCO) , which accounts for about 2.7% on QQQ. I've previously written that I'm bearish on Cisco on an intermediate-term basis. Non-Tech QQQ Stocks Look Iffy, Too Some non-tech QQQ components could weigh down the ETF in 2017 as well. These include biotech and health care companies such as Amgen (AMGN) , Biogen (BIIB) , Celgene (CELG) , Express Scripts (ESRX) and others, which all could suffer if Trump tries to limit drug-price increases. Comcast (CMCSA) also represents a relatively large QQQ weighting (about 3%), but the cable giant could suffer from continued "cord cutting" by consumers. Tax Cuts Won't Help QQQ Stocks Trump's plan to lower the effective U.S. corporate tax rate won't materially benefit QQQ components. After all, large tech and health care firms in the Nasdaq 100 already g
We have a nice gainer here, let's unload it

SOLD OLED MAR 75 CALL AT 6.40 (in at 2.70)
The hammer candle retest of the channel resistance-turned-support line on the Russell 2000...
The SPDR S&P Biotech ETF (XBI) was trading in a four month symmetrical triangle b...
Join me later today as I bring back Toni Hanser to a webinar.  Toni has been away for...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.